Comparative Pharmacology
Head-to-head clinical analysis: APRESOLINE ESIDRIX versus TEKTURNA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APRESOLINE ESIDRIX versus TEKTURNA.
APRESOLINE-ESIDRIX vs TEKTURNA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Apresoline (hydralazine) is a direct-acting vasodilator that relaxes arteriolar smooth muscle via unknown mechanism; Esidrix (hydrochlorothiazide) is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule.
Direct renin inhibitor that binds to renin, inhibiting the conversion of angiotensinogen to angiotensin I, thereby reducing angiotensin II levels and decreasing vasoconstriction and aldosterone secretion.
Hydralazine (Apresoline): Oral, initial 10 mg 4 times daily for first 2-4 days, then increase to 25 mg 4 times daily for first week, then 50 mg 4 times daily thereafter. Maximum daily dose: 300 mg. Hydrochlorothiazide (Esidrix): Oral, initial 12.5-25 mg once daily, may increase to 50 mg once daily if needed.
150 mg orally once daily, starting dose; may increase to 300 mg once daily after 2-4 weeks if blood pressure not controlled, with or without food.
None Documented
None Documented
Hydralazine: 2-8 h (prolonged in renal impairment); Hydrochlorothiazide: 6-15 h (mean 10 h, increased in renal failure).
Terminal elimination half-life is approximately 24 hours (range 20–40 hours), supporting once-daily dosing.
Renal: Hydralazine 85-90% as metabolites, 5-10% unchanged; Hydrochlorothiazide 95% as unchanged drug. Biliary/fecal: Hydralazine <10%.
Primarily renal (88% as unchanged drug and metabolites, 33% as unchanged aliskiren); biliary/fecal elimination accounts for approximately 12%.
Category C
Category C
Antihypertensive
Antihypertensive